In August 2018, FDA has approved an expanded label for pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations, based on results of the KEYNOTE-189 trial [61]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.